Latest "Misonix, Inc." News Stories
Here are the most relevant search results for "Misonix, Inc." found in our extensive news archives from over 250 global news sources.
More Information about Misonix, Inc. on BioPortfolio
In addition to our news stories we have dozens of PubMed Articles about Misonix, Inc. for you to read. Along with our medical data and news we also list Misonix, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Misonix, Inc. Companies for you to search.
Showing "Misonix" News Articles, all 8
MISONIX, Inc. (MSON) CEO Stavros Vizirgianakis on Q4 2018 Results - Earnings Call Transcript
SummaryMisonix Inc Misonix is a medical technology company that provides ultrasonic surgical devices for neurosurgical, spinal, advanced wound care and general surgery procedures. The company's major products include BoneScalpel cutting system; SonaStar surgical aspirator; SonicOne wound cleansing and debridement system. Its products are used for wound debridement, cosmetic surgery, neurosurgery, ...
Misonix (MSON) Presents At Canaccord Genuity 38th Annual Growth Conference - Slideshow
5 Top Weekly NASDAQ Biotech Stocks: resTORbio Leads the Pack
resTORbio, ADMA Biologics, Misonix, Novus Therapeutics and Innovate Biopharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index. The post 5 Top Weekly NASDAQ Biotech Stocks: resTORbio Leads the Pack appeared first on Investing News Network.
SummaryMisonix Inc Misonix is a medical technology company that provides ultrasonic surgical devices for neurosurgical, spinal, advanced wound care and general surgery procedures. The company's major products include BoneScalpel cutting system; SonaStar surgical aspirator; SonicOne wound cleansing and debridement system. Its products are used for wound debridement, cosmetic surgery, neurosurgery, ...
Misonix Turns In Solid Quarter
It's Raining FDA Approvals, MSON Muscling Up, RDHL To Report Data In Aug.
Today's Daily Dose brings you news about FDA approval of Astellas Pharma's Myrbetriq/VESIcare combo for overactive bladder; MediciNova's progress in MN-166 in alcohol dependence and withdrawal; regulatory nod for expanded use of DARZALEX; Ultragenyx Pharma's near-term catalysts; solid financial results of Misonix and Xencor's upcoming clinical trial plans.
MISONIX's (MSON) CEO Stavros Vizirgianakis on Q3 2018 Results - Earnings Call Transcript
